ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeks BLA resubmission on track for calendar Q1 2025 Entered into agreements for warrant inducement transaction expected to result in up to ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

According to InvestingPro data, AbbVie maintains a robust gross profit margin of 70. ... pivotal trial results for wet age-related macular degeneration in 2026. Recent developments also include ...

VAUGHAN, Ontario - Bausch + Lomb Corporation (NYSE/TSX: BLCO), an established player in the eye health sector ... a form of advanced dry age-related macular degeneration, impacts around one ...

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into a collaboration to ...

Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...

The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema ... and develops product candidates for treating patients with eye, allergic and ...

Study from Case Western Reserve University and VA Northeast Ohio Healthcare System examines genetic risk profiles across ...